347 related articles for article (PubMed ID: 21425979)
1. Novel potent pharmacological cyclin-dependent kinase inhibitors.
Węsierska-Gądek J; Chamrád I; Kryštof V
Future Med Chem; 2009 Dec; 1(9):1561-81. PubMed ID: 21425979
[TBL] [Abstract][Full Text] [Related]
2. Whether to target single or multiple CDKs for therapy? That is the question.
Węsierska-Gądek J; Maurer M; Zulehner N; Komina O
J Cell Physiol; 2011 Feb; 226(2):341-9. PubMed ID: 20836132
[TBL] [Abstract][Full Text] [Related]
3. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
[TBL] [Abstract][Full Text] [Related]
4. Cyclins and related kinases in cancer cells.
Malumbres M
J BUON; 2007 Sep; 12 Suppl 1():S45-52. PubMed ID: 17935277
[TBL] [Abstract][Full Text] [Related]
5. Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development.
Kaubisch A; Schwartz GK
Cancer J; 2000; 6(4):192-212. PubMed ID: 11038138
[TBL] [Abstract][Full Text] [Related]
6. Selective cyclin-dependent kinase inhibitors discriminating between cell cycle and transcriptional kinases: future reality or utopia?
Wesierska-Gadek J; Krystof V
Ann N Y Acad Sci; 2009 Aug; 1171():228-41. PubMed ID: 19723060
[TBL] [Abstract][Full Text] [Related]
7. Progress in the evaluation of CDK inhibitors as anti-tumor agents.
McInnes C
Drug Discov Today; 2008 Oct; 13(19-20):875-81. PubMed ID: 18639646
[TBL] [Abstract][Full Text] [Related]
8. The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications.
Węsierska-Gądek J; Kramer MP
Expert Opin Investig Drugs; 2011 Dec; 20(12):1611-28. PubMed ID: 22017180
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors.
Pavletich NP
J Mol Biol; 1999 Apr; 287(5):821-8. PubMed ID: 10222191
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy.
Senderowicz AM
Cancer Chemother Biol Response Modif; 2001; 19():165-88. PubMed ID: 11686013
[TBL] [Abstract][Full Text] [Related]
11. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15.
Iavarone A; Massagué J
Nature; 1997 May; 387(6631):417-22. PubMed ID: 9163429
[TBL] [Abstract][Full Text] [Related]
12. Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells.
Yenugonda VM; Deb TB; Grindrod SC; Dakshanamurthy S; Yang Y; Paige M; Brown ML
Bioorg Med Chem; 2011 Apr; 19(8):2714-25. PubMed ID: 21440449
[TBL] [Abstract][Full Text] [Related]
13. Small-molecule cyclin-dependent kinase modulators.
Senderowicz AM
Oncogene; 2003 Sep; 22(42):6609-20. PubMed ID: 14528286
[TBL] [Abstract][Full Text] [Related]
14. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
Santo L; Siu KT; Raje N
Semin Oncol; 2015 Dec; 42(6):788-800. PubMed ID: 26615126
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510: identification of 3' substituted indolones as a scaffold for the development of neuroprotective drugs.
Johnson K; Liu L; Majdzadeh N; Chavez C; Chin PC; Morrison B; Wang L; Park J; Chugh P; Chen HM; D'Mello SR
J Neurochem; 2005 May; 93(3):538-48. PubMed ID: 15836613
[TBL] [Abstract][Full Text] [Related]
16. Control of vascular cell proliferation and migration by cyclin-dependent kinase signalling: new perspectives and therapeutic potential.
Andrés V
Cardiovasc Res; 2004 Jul; 63(1):11-21. PubMed ID: 15194457
[TBL] [Abstract][Full Text] [Related]
17. [Cyclin-dependent kinase inhibitors in mammal cells].
Jiang H; Wang YC
Sheng Li Ke Xue Jin Zhan; 1996 Apr; 27(2):107-12. PubMed ID: 9592231
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Blachly JS; Byrd JC; Grever M
Semin Oncol; 2016 Apr; 43(2):265-73. PubMed ID: 27040705
[TBL] [Abstract][Full Text] [Related]
19. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors.
Collins I; Garrett MD
Curr Opin Pharmacol; 2005 Aug; 5(4):366-73. PubMed ID: 15964238
[TBL] [Abstract][Full Text] [Related]
20. ATP-noncompetitive CDK inhibitors for cancer therapy: an overview.
Abate AA; Pentimalli F; Esposito L; Giordano A
Expert Opin Investig Drugs; 2013 Jul; 22(7):895-906. PubMed ID: 23735075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]